These data suggest that patients with FGFR1-amplification and MYC-overexpression may benefit from anti-FGF/FGFR therapies and that the evaluation of c-Myc levels may serve as a biomarker for the response to FGF/FGFR inhibition in FGF-addicted cancers. Here, FGFR1 is linked to cancer.